Venlafaxine Stella 37.5mg Treatment of severe depression (6 blisters x 10 tablets)

Dosage form Box of 6 blisters x 10 tablets
Specifications Vendafaxine

Ingredient

Composition information	Content
Vendafaxine	37.5mg

Uses

Indication

Venlafaxine Stella 37.5 mg is indicated in the following cases:

Treatment of severe severe attacks (spreading anxiety disorders, social anxiety and panic disorders, with or without fear of space).

Prevention of severe depression.

Pharmacology

Venlafaxine's antidepressant mechanism in humans is thought to be due to neurotransmitter activity in the central nervous system. Pre-clinical studies have shown Venlafaxine and active metabolites, O-Desmethidlvenlafaxine (ODV), which are strong inhibitors of recovery Serotonin and norepinephrine in neuron neuron and inhibit the re-acquisition of dopamine.

In vitro, Venlafaxine and ODM have no significant affinity for receptors Muscarin, histamine or (alpha) -1 adrenergic. The pharmacological activity on these receptors is thought to be related to various effects such as cholinergic resistance, sedation and cardiovascular effects as seen in other mental drugs. Venlafaxine and ODV do not have the activity of inhibiting monoamine oxidase (Mao).

Dynamic pharmacokinetics

absorption: at least 92% Venlafaxine is absorbed after taking single dose of fast release. Absolute bioavailability is 40 - 45% through the first metabolism. Food does not affect the bioavailability of Venlafaxine and ODV.

Distribution: Venlafaxine and ODV are linked to low plasma proteins (in order of 27% and 30%).

Metabolic: Venlafaxine is metabolized mainly through the liver. Venlafaxine is converted into the main active metabolic substance, O-Desmethidilvenlafaxine (ODV) by CYP2D6; Venlafaxine has also been converted into N-Desmethidvenlafaxine, a less active auxiliary metabolites by CYP3A4. Venlafaxine is a weak inhibitor of CYP2D6. Venlafaxine does not inhibit CYP1A2, CYP2C9 or CYP3A4.

Elimination: Venlafaxine and the metabolites of the drug are excreted mainly through the kidneys. About 87%of the doses of venlafaxine are found in urine within 48 hours, in the form of venlafaxine constant (5%), non -combined ODV (29%), conjugated ODV (26%) or other non -active auxiliary metabolites (27%). The average stability of the plasma of venlafaxine and ODV is 1.3 ± 0.6 l/h/k kg and 0.4 ± 0.2 l/h/k/kg.

Before taking Venlafaxine Stella 37.5mg Treatment of severe depression (6 blisters x 10 tablets)

How to use

Take oral use.

Dosage

Severe depression: The recommended starting dose is 75 mg, once a day. Patients who do not respond to the starting dose of 75 mg/day may increase the dose to a maximum dose of 375 mg/day. Increasing dose can be done for 2 weeks or more.

Disseminate anxiety disorders: The recommended starting dose is 75 mg, once a day. Patients who do not respond to the starting dose of 75 mg/day may increase the dose to a maximum dose of 225 mg/day. Increasing dose can be done for 2 weeks or more.

Social anxiety disorders: The recommended dose is 75 mg once a day. There is no evidence that higher dose brings more benefits. However, the patient does not respond to the starting dose of 75 mg/day, which may increase the dose to a maximum dose of 225 mg/day. Increasing dose can be done for 2 weeks or more.

Panic disorders: The recommended dose of 37.5 mg/day for 7 days. Then increase the dose to 75 mg/day. Two patient does not respond to a dose of 75 mg/day may increase to a maximum dose of 225 mg/day. Increasing dose can be done for 2 weeks or more.

Prevention of severe depression: long -term treatment may also be suitable to prevent recurrence of severe depression. In most cases, the recommended dose to prevent the recurrence of severe depression is similar to the treatment.

Elderly: Be careful in treating the elderly. Always use the lowest dose effectively and the patient must be carefully monitored when increasing the dose.

Patients with liver failure/ renal failure: Depending on the different clearance of each individual, adjust the dose appropriately as desired. Increasing dose should only be done after clinical assessments due to unwanted effects correlate the dose. Should use the lowest effect.

Note: The above dose is for reference only. Specific dosage depends on the condition and level of progression of the disease. For a suitable dose, you need to consult a doctor or medical specialist.What do

do when overdose? Electrolyte abnormalities (such as extending the QT range, closing of the branch, extending the QRS), sinus tachycardia and ventricle, slow heart rate, Hypotension , loss of awareness (from drowsiness to coma), Ly muscle, epilepsy, dizziness, liver necrosis and death have been reported.

Handling good airways, ensuring enough oxygen and ventilation. Monitor heart rate and survival signs. If necessary, gastric lavage with large gastric catheter has an appropriate airway protection that can be indicated if done early when taken or new symptoms.

Should use activated carbon. Because the distribution of the drug is large, the method of rapid diuretics, appraisal, absorbing the adsorbent and changing blood is not beneficial. There is still no specific detoxifying substance for vendafaxine.

What to do when you forget a dose? However, if close to the next dose, skip the forgotten dose and take the next dose at the time as planned. Note that it should not be used double the prescribed dose.

Side Effects

When using venlafaxine 37.5 mg , you may experience unwanted effects (ADR).

Common, ADR> 1/100

Systemic: weakness, sweat, panic, tremor, paresthesia, chills or fever, increase or lose weight, shortness of breath;

Neurological: headache , insomnia, drowsiness, dizziness, anxiety, agitation, dreaming, confusion;

Digestive: Anorexia, diarrhea , indigestion, abdominal pain, nausea, dry mouth , constipation, vomiting;

Skin: skin, itching;

Cardiovascular: Hypertension depends on the dose, vasodilation, chest drums;

Eyes: visual disorders;

Kidney: regular urination;

musculoskeleton: arthritis, muscle pain;

Genital: Destiny of genital function.

Uncommon, 1/1000

Neurology: illusion;

Skin: light sensitive reactions;

Cardiovascular: lower blood pressure, fainting, arrhythmia, tachycardia;

muscle: muscle spasm;

Liver: Increasing liver enzyme can recover.

Instructions on how to handle ADR

When experiencing side effects of the drug, it is necessary to stop using and notify the doctor or go to the nearest medical facility for timely treatment.

Warnings

Before using the drug you need to read the instructions carefully and refer to the information below.

contraindicated

venlafaxine 37.5 mg contraindicated in the following cases:

Hypersensitivity to any ingredients of the drug.

Cases of high risk of arrhythmia, uncontrolled hypertension.

Children and teenagers under 18 years old.

Pregnant women.

venlafaxine must be stopped at least 7 days before starting treatment with non -recovery Mao inhibitors.

venlafaxine must not start at least 14 days after stopping treatment with non -recovery Mao inhibitors.

Be cautious when used

Patients with a recent history of myocardial infarction or the disease is likely to be severe when the heart rate increases. Due to the risk of dosage hypertension, the blood pressure is required to be monitored regularly when treated. Need to check the serum cholesterol level when long -term treatment.

Be cautious when taking Venlafaxine for patients with liver or kidney failure moderate to severe and adjust the dose as needed.

Venlafaxine is used with patients with a history of epilepsy and avoids for people with unstable illnesses, should stop the drug in any patient developing epilepsy or increasing epilepsy frequency.

Be cautious with patients with a history of bleeding disorders, mild manic or manic.

Patients with glaucoma or at risk of closed angle glaucom should be closely monitored.

Report immediately to the doctor if there are signs of rash, urticaria or allergic reactions associated with vendafaxine.

Patients, especially the elderly, should be cautious with the risk of being dizzy, unstable due to standing hypotension.

Symptoms of drug stops or sudden reduction of venlafaxine dose include fatigue, drowsiness, headache, nausea, vomiting, anorexia, chest drum, dizziness, dry mouth, diarrhea, insomnia, agitation, anxiety, stress, confusion, mild, abnormal, sweating and dizziness.

venlafaxine Stella contains lactose. This drug should not be used for patients with rare genetic problems galactose intolerance, total lactase enzyme deficiency or poorly absorbed glucose-galactose.

The ability to drive and operate machinery

Like other antidepressants, Venlafaxine can impair the ability to work and if any effects occur, patients should not drive or operate machinery.

Pregnancy

research on mice shows that when the mother uses the mother from pregnancy until the milk is stopped, there is a decrease in mass and increase the premature death in the baby mice and also increase death in the mice in the first 5 days of breastfeeding.

There is no complete and well -controlled research on pregnant women. Because animal research is not always predicted in humans, it is only used during pregnancy when it is really necessary.

The period of breastfeeding

venlafaxine is excreted through breast milk. Due to the risk of serious unwanted effects for breastfeeding children, it is recommended to decide or stop breastfeeding or stop using the drug, after considering the importance of the drug for the mother.

Drug interaction

CYP3A4 inhibitors: Used with CYP3A4 inhibitors (Atazanavir, Clarithromycin, Indinavir, Itraconazole, Voriconazol , Posaconazol, Ketoconazole, Nelfinavir, Ritonavir Ritonavir and telithromycin) may increase the concentration of vendafaxine and O-Desmethylvenlafaxine. Therefore, it is necessary to be cautious when the patient is taking treatment therapy simultaneously inhibitors CYP3A4 and Venlafaxine.

Lithi: Serotonin syndrome can occur when using simultaneously venlafaxine and lithium.

Monoamine oxidase inhibitors:

Some serious unwanted effects have been reported in new patients who stop using Monoamine Oxidase inhibitors (IMAO) and start using Venlafaxine or vice versa. Therefore, do not use Venlafaxine in combination with Mao inhibitors, or for at least 14 days after stopping using Mao inhibitors.

Central nerve stimulants: Be careful when combining Venlafaxine with other central nervous stimulants.

Storage

Storage in closed packaging, dry place, temperature not exceeding 30 ° C.

Other drugs

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.